Loading
HKSEHealthcareBiotechnology
Latest quote
HK$3.18
−HK$0.15 · -4.50%
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
Latest quote
HK$3.18
−HK$0.15 · -4.50%
Regular session · HKT · Market data may be delayed.
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
Day range
Current HK$3.18
52-week range
Current HK$3.18
Regular session · HKT · Market data may be delayed.
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
Day range
Current HK$3.18
52-week range
Current HK$3.18
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 164.47M CNY | 363.53M CNY | 311.57M CNY | 182.65M CNY | 84.01M CNY |
| Selling, general, and administrative | 59.1M CNY | 81.23M CNY | 136.67M CNY | 43.43M CNY | 48.06M CNY |
| Operating expenses | 223.57M CNY | 444.75M CNY | 448.24M CNY | 226.08M CNY | 132.08M CNY |
| Interest income | 10.23M CNY | 27.65K CNY | 26.83M CNY | 3.55M CNY | 964K CNY |
| Interest expense | 2.3M CNY | 1.53M CNY | 442K CNY | 426K CNY | 4.53M CNY |
| Depreciation and amortization | 1.41M CNY | 1.01M CNY | 537K CNY | 409K CNY | 276K CNY |
| Operating income | −223.57M CNY | −444.75M CNY | −448.24M CNY | −226.08M CNY | −132.08M CNY |
| Net income | −244.97M CNY | −381.79M CNY | −939.31M CNY | −190.24M CNY | −221.15M CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
